Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Guillain Barr e syndrome in COVID-19:A scoping review

    Authors: Imran Ahmad; Farooq Azam Rathore

    doi:10.1101/2020.06.13.20130062 Date: 2020-06-16 Source: medRxiv

    Introduction The novel coronavirus (COVID19) can result in several neurological complications. Guillain-Barre Syndrome MESHD ( GBS MESHD) is one of them and has been reported from different parts of the world in this pandemic. It is an acute post-infectious polyneuropathy HP polyneuropathy MESHD. The review aims to summarize the demographic features, clinical presentation, diagnostics workup, and management strategies of COVID-19 associated GBS MESHD reported in the literature. Material and method We searched Medline, PubMed Central, SCOPUS, and Google Scholar using pre-defined keywords, with no time limits and in the English language only. We aimed to include all kinds of manuscripts. The last search was done on 18th May 2020. Demographics, clinical features, diagnostic workup, management, and outcomes were documented in the datasheet. Results We identified 24 cases of COVID-19 associated GBS MESHD. Most of the cases were reported from Italy followed by the USA. The majority were males TRANS (18 /24) The age TRANS ranged from 23 -84 years. The clinical presentation was typical sensory-motor GBS MESHD in most. Nine patients had facial palsy HP of which five had bilateral involvement. Two patients had bilateral abducent nerve palsy MESHD while two presented as paraparetic GBS MESHD variant with autonomic dysfunction. Electrodiagnostics was performed in 17 patients only and 12 had typical features of acute inflammatory demyelinating polyneuropathy MESHD polyneuropathy HP. Intravenous immunoglobulins were the preferred mode of treatment in most of the patient. There was one death MESHD, and most were discharged to rehabilitation or home. Conclusion GBS MESHD is a frequent neurological complication associated with COVID-19. There is no clear causative relationship between GBS MESHD, and COVID-19 at present, and more data are needed to establish the casualty. However, most cases have a post-infectious onset with male TRANS preponderance. Most of the cases have a typical presentation but some may present in an atypical way. Prognosis is generally good.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.